Compare JD & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JD | WAT |
|---|---|---|
| Founded | 2006 | 1958 |
| Country | China | United States |
| Employees | 776682 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 33.5B |
| IPO Year | N/A | 1996 |
| Metric | JD | WAT |
|---|---|---|
| Price | $29.17 | $374.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $39.27 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 10.1M | 1.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.17 | $104.66 |
| Revenue Next Year | $6.01 | $10.40 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.51 | $275.05 |
| 52 Week High | $36.86 | $414.15 |
| Indicator | JD | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 68.90 |
| Support Level | $27.93 | $372.18 |
| Resistance Level | $29.51 | $394.24 |
| Average True Range (ATR) | 0.79 | 11.79 |
| MACD | -0.40 | 3.67 |
| Stochastic Oscillator | 9.95 | 84.75 |
JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.